Core Viewpoint - Innotech (688253) reported a decline in both revenue and net profit for the year 2025, while also announcing progress in new business and product developments [1] Business Performance - Innotech achieved an operating revenue of 422 million yuan in 2025, a year-on-year decrease of 32.08% - The net profit attributable to shareholders was 146 million yuan, down 40.84% year-on-year - The fluctuations in performance were primarily influenced by policy adjustments in the in vitro diagnostics industry, intensified competition in the respiratory testing sector, and a weaker flu season compared to the previous year [2] Business Progress - The company disclosed that its first single-molecule detection instrument and reagents for neurological testing have obtained product registration certificates - New registrations were also achieved in the international market, including EU IVDR and US FDA certifications - Collaborations with platforms like JD.com and Meituan are enhancing the brand building for home testing, which is expected to be a focal point for future business expansion [3] Company Status - From November 18 to December 1, 2025, Innotech conducted a shareholder reward activity, providing prizes to stockholders, reflecting the company's efforts to maintain shareholder relations [4]

2月11日，英诺特发布公告称，2025年度公司实现营业总收入4.22亿元，同比下降32.08%；归母净利润 为1.46亿元，同比下降40.84%。 （英诺特公告） 2025年，流感样病例在多数时间低于2024年同期，导致公司营业收入显著下降。尽管面临挑战，公司仍 在研发和市场投入上保持高水平，尤其是在国际市场和新业务方面。公司在2025年新获批十余项产品注 册证，并与京东、美团等线上渠道合作，建立了一定的品牌知名度，为2026年的发展奠定基础。 ...

Group 1: Major Announcements - Unisplendour plans to raise no more than 5.57 billion yuan through a private placement to acquire a 6.98% stake in New H3C and for other projects [2] - Zhongwei Semiconductor intends to establish an IPM production line project in Ziyang, Sichuan, using 1.21 billion yuan of leftover IPO funds [2] - Kaiying Network has signed a settlement agreement with Legend IP, which is expected to positively impact the company's profit by approximately 200 million yuan [2] Group 2: Project Developments - Blue Ocean Huaten plans to invest 8 million yuan in Wanren Technology to support its daily operations and AI project development [4] - Yuedian Power A has successfully put into operation the expansion project of the Huizhou Power Plant, which includes two 1000MW units [7] - Longmag Technology intends to raise up to 760 million yuan for its second phase project in Vietnam and chip inductor manufacturing [8] Group 3: Financial Performance - Top Group expects a net profit of 2.6 billion to 2.9 billion yuan for 2025, a decrease of 3.35% to 13.35% year-on-year due to rising raw material costs and increased market competition [20] - Jingchen Technology reported a net profit of 871 million yuan for 2025, a 6% increase year-on-year, with record high sales of over 174 million chips [21] - Guodian Xintong's net profit for 2025 is projected at 678 million yuan, a decline of 16.91% year-on-year, primarily due to increased credit impairment losses and tax expenses [22] Group 4: Shareholder Actions - Jieshun Technology's actual controller plans to reduce holdings by up to 2.8% of the company's shares [27] - Lihexing's controlling shareholder and concerted actors plan to collectively reduce their holdings by up to 1% [27] - Kory Technology's shareholders plan to reduce their holdings by a total of up to 3.13% [29] Group 5: Stock Buybacks - Quzhou Dongfeng plans to repurchase shares worth between 50 million and 100 million yuan, with a maximum price of 6.48 yuan per share [30]

Core Viewpoint - In the 2025 performance report, Innotec (688253) experienced significant declines in both revenue and net profit, attributed to industry policy impacts and intensified competition in its main business areas [1] Group 1: Financial Performance - Innotec reported a revenue of 422 million yuan for 2025, representing a year-on-year decrease of 32.08% [1] - The company achieved a net profit attributable to shareholders of 146 million yuan, down 40.84% year-on-year [1] Group 2: Industry Context - The in vitro diagnostic industry faced challenges due to regulatory policies related to medical insurance and taxation [1] - Increased competition in the specific testing fields of respiratory and digestive pathogens further pressured the company's performance in 2025 [1]

英诺特2月11日发布的2025年度业绩快报显示，公司报告期内实现营业收入4.22亿元，同比下降 32.08%；归属于上市公司股东的净利润1.46亿元，同比下降40.84%；基本每股收益1.07元。 英诺特2月11日发布的2025年度业绩快报显示，公司报告期内实现营业收入4.22亿元，同比下降 32.08%；归属于上市公司股东的净利润1.46亿元，同比下降40.84%；基本每股收益1.07元。 ...

证券代码：688253 证券简称：英诺特 公告编号：2026-005 （一）报告期的经营情况、财务状况及影响经营业绩的主要因素说明 1、经营情况及财务状况 | | | | 单位：万元 | | --- | --- | --- | --- | | 项目 | 本报告期 | 上年同期 | 增减变动幅度（％） | | 营业总收入 | 42,203.03 | 62,138.92 | -32.08 | | 营业利润 | 16,052.52 | 27,618.13 | -41.88 | | 利润总额 | 16,062.48 | 27,652.61 | -41.91 | | 归属于母公司所有者的净 利润 | 14,604.47 | 24,685.97 | -40.84 | | 归属于母公司所有者的扣 除非经常性损益的净利润 | 12,007.95 | 21,775.24 | -44.86 | | 基本每股收益（元） | 1.07 | 1.81 | -40.88 | | 加权平均净资产收益率 | 7.20% | 12.74% | 下降 5.54 个百分点 | | | 本报告期末 | 本报告期初 | 增减变动幅度（％） | | 总 ...

（原标题：英诺特(688253.SH)业绩快报：2025年度净利润1.46亿元，同比下降40.84%） 格隆汇2月11日丨英诺特(688253.SH)公布2025年度业绩快报，报告期内，公司实现营业总收入4.22亿 元，同比下降32.08%；实现归属于母公司所有者的净利润1.46亿元，同比下降40.84%。 2025年，公司所在的体外诊断行业受到医保监管政策、税收政策等行业政策影响，叠加公司主营业务所 在的呼吸道病原体、消化道病原体等细分检测领域受到行业竞争加剧的影响，导致公司2025年全年业绩 承压。 ...

英诺特公告称，2025年度公司实现营业总收入42,203.03万元，同比下降32.08%；归属于母公司所有者 的净利润14,604.47万元，同比下降40.84%。业绩下滑主要因体外诊断行业受政策影响，细分检测领域 竞争加剧，且病原体流行情况不如2024年。同时，公司人力成本、研发开支与市场投入费用增加，使利 润指标下滑更大。不过，公司在研发和营销端取得进展，为2026年发展奠定基础。 ...

证券代码：688253 证券简称：英诺特 公告编号：2026-004 二、对公司的影响 上述资质的取得，拓宽了公司产品的种类，进一步提高了公司的市场拓展能 力及核心竞争力。 三、风险提示 上述产品的实际销售受到市场需求、市场竞争以及公司市场推广效果等多种 因素影响，利润贡献具有不确定性，尚无法预测上述产品对公司未来经营业绩的 影响。敬请广大投资者谨慎投资、注意投资风险。 北京英诺特生物技术股份有限公司关于公司近期获 得资质情况的自愿披露公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、公司近期获得资质的基本情况 北京英诺特生物技术股份有限公司（以下简称"公司"）近期新取得产品资 质 1 项，具体情况如下表所示： | 北京英诺特生物技 | | 京械注准 | 2026/2/5 | | | --- | --- | --- | --- | --- | | 术股份有限公司 | （GFAP）测定试剂盒 | 20262400042 | | | | 获批主体 | 产品名称 胶质纤维酸性蛋白 （单分子免疫荧光法） | 注册证号（备 ...

英诺特公告称，公司近期新取得产品资质1项，为胶质纤维酸性蛋白（GFAP）测定试剂盒（单分子免疫 荧光法），注册证号为京械注准20262400042，发证日期为2026年2月5日，有效期至2031年2月4日。该 产品用于体外定量检测人体血浆中胶质纤维酸性蛋白含量，是公司神经系统检测领域首张试剂产品注册 证。这拓宽了公司产品种类，提升市场拓展及核心竞争力，但产品销售受多种因素影响，对业绩影响尚 无法预测。 ...